Clinical reports lend support to this mechanistic overlap – notably, therapies targeting the IL-23/IL-17 pathway (e.g. ustekinumab, an IL-12/23 p40 inhibitor used in psoriasis) have shown efficacy in treating refractory “mechanic’s hands” in an antisynthetase syndrome patient (7). This evidence concerns the gene IL23A and psoriasis.